Power to the Patients
Ukupno trajanje:
28 h 46 min
The Gout Narrative Keeping Patients Sick and What Crystalys Therapeutics Is Doing Differently
Power to the Patients
36:22
Developing a treatment for Alzheimer's in the world of AI with Sacha Schermerhorn
Power to the Patients
33:55
How Neuroplasticity Is Shaping the Next Generation of Psychiatric Medicines
Power to the Patients
33:57
70% Remission for Postpartum Depression? The Psychedelic Breakthrough
Power to the Patients
35:54
Why Psychiatry Is Finally Breaking Free From Dopamine
Power to the Patients
29:08
Precision Medicine Got Kidney Disease Wrong—Until Now
Power to the Patients
42:13
Why Dr. Ken Sharlin Believes Most Neurological Diseases Are Reversible
Power to the Patients
37:54
Why Serotonin Isn’t Outdated, Our Thinking Is
Power to the Patients
40:49
Who Really Protects Patients in Clinical Trials? With Dr. Lara Shirikjian
Power to the Patients
39:54
Turning Pain Into Progress: How Sonia Prashar Built a Mission Around Mental Health
Power to the Patients
33:41
The Synapse Secret: How One Molecule Normalized Brain Activity in Fragile X Patients
Power to the Patients
38:38
Beyond Dopamine: Why Traditional Schizophrenia Treatments Miss 50% of Patient Needs
Power to the Patients
31:48
The 20-Year Industry Secret: Redefining Neurodegenerative Treatment
Power to the Patients
53:14
One Mechanism, Three Conditions: A New Direction in Neurological Treatment
Power to the Patients
35:28
Why Traditional Psychedelics Miss 90% of Neurology Patients - And The Solution
Power to the Patients
42:21
Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo
Power to the Patients
39:56
Why Clinical Trial Speed Kills Success - And What Top Sponsors Do Instead ft. Steve Brannan
Power to the Patients
40:54
Dr. Anantha Shekhar on the Convergence of Psychiatry, Neurology, and the Next Era of Brain Medicine
Power to the Patients
50:05
Ram Mukunda, CEO of IGC Pharma, on Innovation and Hope in Alzheimer’s Care
Power to the Patients
39:42
Brandon Bentzley, CSO and Co-founder of Magnus Medical, on Precision Psychiatry and Rewiring Depression
Power to the Patients
68:18
Sarah MacCallum & Melissa Gaines- Clinical Operations Leaders at Annovis Bio
Power to the Patients
50:28
Daniel O'Connell, CEO of Acumen Pharmaceuticals, on Oligomers, Innovation, and Hope in Alzheimer’s
Power to the Patients
45:45
Michael Gold, Chief R&D Officer at Compass Pathways
Power to the Patients
55:40
Matthew Leoni, CMO of Merida Biosciences, on Navigating the Challenges and Opportunities in Neuroscience Drug Development
Power to the Patients
56:17
Gerard Sanacora, Professor at Yale, on glutamate, GABA, and the next era of depression treatment
Power to the Patients
53:47
Backing Breakthroughs in Psychedelics
Power to the Patients
39:35
Joel Raskin, CMO of Arrivo Bio talks about unlocking the future of psychiatry
Power to the Patients
47:26
Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass General Center on the Neuroscience of Psychedelics
Power to the Patients
42:33
Spyros Papapetropoulos, CEO of Neuphoria
Power to the Patients
42:17
Steve Gourlay, CEO of Actinogen
Power to the Patients
41:13
Boehringer Ingelheim: Christine Sakdalan and Mike Jablonski talk precision psychiatry
Power to the Patients
40:32
John Krystal: Advancing Ketamine Research & Psychiatry at Yale
Power to the Patients
61:02
Next-Gen Treatments for Anxiety and Depression Disorders
Power to the Patients
45:01
Precision Psychiatry and Emerging Technologies
Power to the Patients
63:28
From Culture to Care: The Framework of Patient Centricity
Power to the Patients
33:20
Unraveling Mysteries of the Brain Through Neuroscience Research
Power to the Patients
48:39
Harnessing Precision Medicine to Redefine Psychiatric Treatment
Power to the Patients
46:27
Breaking New Ground with Psilocybin
Power to the Patients
48:48
Bringing the Consumer Experience to Clinical Research
Power to the Patients
24:20
A New Frontier of Psychedelic Therapies
Power to the Patients
35:34
